echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Concept validation of potential cure therapy for type 1 diabetes

    Concept validation of potential cure therapy for type 1 diabetes

    • Last Update: 2020-06-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    T1D is a kind of autoimmune diseaseThe β cells in the islets of Langerhans of the patients are damaged, unable to provide enough insulin to maintain the normal level of blood sugar, which leads to hyperglycemia, which results in excessive drinking, urination, eating, weight loss, blurred vision, etc., even life-threateningIn the past, the main treatment of T1D was injection of exogenous insulin, but even through insulin treatment, patients still have the risk of long-term complications, such as macular edema and retinopathy (which can lead to blindness), renal failure, neurological and vascular diseases< br / > the principle of regenerative therapy developed by semma is to produce a large number of SC islets from human pluripotent stem cellsIn 2014, Professor Doug Melton's laboratory at Harvard University developed the breakthrough stem cell differentiation technology and authorized it to semma for cell therapySC islets is functionally equivalent to natural islets of LangerhansIt is used to sense the glucose level in human body and release insulin accurately, with good repeatability and stability< br / > ▲ the mechanism of SC islets cell therapy (photo source: semma company website) < br / > in the preclinical study, SC islets were delivered to non-human primates under immunosuppression, and could exist stably in their liver for more than six weeks, with insulin demand reduced by more than 60%In another study, SC islets were encapsulated in a new immune protection device developed by semma company and delivered to pigs without immunosuppressionThe device can provide immune protection, maximize the survival of SC islets and reduce rejectionSemma plans to conduct two clinical trials starting in the first half of 2020, targeting patients with diabetes and hypoglycemia who are difficult to treat< br / >, "This innovative treatment brings hope to millions of people around the world who have type 1 diabetes." < br / > reference < br / > [1] semitherapeutics announcements pre clinical proof of concept in two lead programs in type 1 diabetesRetrieved July 2, 2019, from < br / > [2] about semitherapeuticsRetrieved July 2, 2019, from < br / > original title: concept validation of potential cure therapy for type 1 diabetes mellitus, islets generated by stem cells
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.